Case under police investigations, says pharma major.
Bharat BioTech said on Saturday that the death of 42-year-old volunteer from Bhopal, who was allegedly administered a dose of its COVID vaccine, Covaxin, in a clinical trial, was “not related” to the vaccine or placebo.
In a statement, the company noted that “with regard to reports of a death in Phase III trials, we would like to state that a volunteer passed away on December 21, 2020 and the death was reported to the People’s College of Medical Sciences & Research Centre by the son of the deceased. The volunteer, at the time of enrolment, had fulfilled all the inclusion and exclusion criteria to be accepted as a participant in the Phase III trial and was reported to be healthy in all the site follow up calls post seven days of his dosing and no AE’s were observed or reported.”
“As per the post-mortem report issued by the Gandhi Medical College, Bhopal that the site received from the Bhopal Police, the probable…
